蘑菇视频APP

Cambridge, MA and Seoul, Korea 鈥� January 8, 2024 鈥� 蘑菇视频APP, the bioplatform innovation company, and Samsung today announced a collaboration aimed at fostering cutting-edge biopharmaceutical innovation poised to transform the world of healthcare through groundbreaking advancements in translational science and medicine.

Through this collaboration, Samsung will work alongside Flagship-founded companies, leveraging Samsung鈥檚 leading technologies and capabilities to accelerate first and best-in-class therapies. The newly formed strategic partnership is an expansion of the ongoing cooperation between Samsung and Flagship. The collaboration between Samsung and Flagship leverages the expertise of both organizations in the areas of life science technology, artificial intelligence, and CDMO services, and extends across Flagship鈥檚 ecosystem of companies.

Key Highlights of the Collaboration:

• Revolutionary Technology: The collaboration will leverage state-of-the-art technology including artificial intelligence, translational medicine, access to high quality clinical samples and Samsung鈥檚 clinical trials infrastructure, and investment by Samsung in Flagship-founded companies.

• Shared Vision: 蘑菇视频APP and Samsung share a common vision of transforming conventional drug discovery and development approaches to help bring new targeted therapeutic solutions to patients. The collaboration is driven by a commitment to pushing the boundaries of what is possible in the bio-pharmaceutical industry.
  

鈥淭his collaboration represents a significant milestone in the pursuit of innovation and scientific excellence,鈥� said Stephen Berenson, Managing Partner, 蘑菇视频APP. 鈥淎s partners, we will bring together 蘑菇视频APP's unparalleled expertise in inventing and developing revolutionary bioplatform companies with Samsung's strategic capabilities to reshape and empower the bio-pharmaceutical landscape, ultimately resulting in bigger leaps for patient care.鈥�

鈥淭his newly formed collaboration is an important evolution of the ongoing relationship between two companies,鈥� said Jaywoo Kim, executive vice president, Samsung C&T. 鈥淲e look forward to seeing the accelerating effect of Samsung鈥檚 various technical expertise and extensive commercial capabilities on the future innovations Flagship and its ecosystem of companies will bring to market.鈥�

For more on the new partnership, view a conversation between Flagship Managing Partner Stephen Berenson and Executive Vice President of Samsung C&T Jaywoo Kim.

About 蘑菇视频APP:

蘑菇视频APP is a biotechnology company that invents and builds platform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $70 billion in aggregate value. To date, Flagship has deployed over $3.6 billion in capital toward the founding and growth of its pioneering companies alongside more than $27 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 40 companies, including鈥疍enali Therapeutics鈥�(NASDAQ: DNLI),鈥疐oghorn Therapeutics鈥�(NASDAQ: FHTX), Generate:Biomedicines,鈥疘nari,鈥疘ndigo Agriculture,鈥疢oderna鈥�(NASDAQ: MRNA),鈥疧mega Therapeutics鈥�(NASDAQ: OMGA),鈥疭ana Biotechnology鈥�(NASDAQ: SANA),鈥疭eres Therapeutics鈥�(NASDAQ: MCRB) and鈥疶essera Therapeutics.

About Samsung C&T:

Samsung C&T Corporation, a dynamic player in industries ranging from construction, trading, fashion and resorts, is actively expanding its portfolio with strategic investments in the biopharmaceutical industry. Since its investing in Samsung Biologics and Bioepis, Samsung Biologics' CDMO production capacity has grown to over 600 kilo liters and contribute greatly to the stabilization of the biopharmaceutical supply chain. In addition, Samsung Bioepis has improved the accessibility of many patients around the world by successfully launching seven biosimilar products. Samsung C&T will continue investment in innovative technologies and businesses that contribute to 'improving quality of life' in various areas of bio & healthcare.

*Note: Samsung C&T, Samsung Biologics, Samsung Bioepis and Samsung Venture Investment Corporation are collectively referred to herein as Samsung.